Thailand In-Vitro Diagnostics Market Outlook

Name: Thailand In-Vitro Diagnostics Market Outlook | 2024-2030
Creator: Next Move Strategy Consulting
Published: 2025-09-24T05:30:00+05:30

About Report

Download Now

Thailand In-Vitro Diagnostics by Product & Service (Reagents & Consumables, Instruments & Devices, and others), by Technique (Clinical Chemistry, Immunoassays, Molecular Diagnostics, and Others), by Testing Site / Channel (Central & Reference Laboratories, Hospital & Physician Labs, Point-of-Care & Retail, and others), by Application / Disease Area (Infectious Diseases, Oncology, Cardiovascular Health, and others)– Opportunity Analysis and Industry Forecast, 2024–2030.

Download PDF

Speak to Our Analyst

Thailand In-Vitro Diagnostics Market Overview

The Thailand In-Vitro Diagnostics Market size was valued at USD 1.03 billion in 2023, and is predicted to reach USD 1.63 billion by 2030, at a CAGR of 6.3% from 2024 to 2030. In-vitro diagnostics (IVD) refers to a wide range of medical tests conducted on samples of bodily fluids, tissues, or cells outside of the body to diagnose diseases, monitor therapy, and assess overall health conditions. These tests are performed in laboratory settings using various techniques and technologies, including immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology.

These tests enable early detection of diseases, allowing for timely intervention and treatment initiation. By providing rapid and accurate results, IVD tests facilitate personalized medicine, guiding tailored treatment approaches based on individual patient characteristics.

Also, in-vitro experiments provide valuable insights into biological systems, enabling scientists and researchers to make significant contributions to fields such as medicine, biotechnology, and pharmacology. They serve as essential tools for understanding fundamental biological processes and developing innovative solutions to address health challenges.

Growing Burden of Chronic Diseases and an Aging Population Fueling Diagnostic Demand

A primary driver for Thailand's IVD market is the increasing prevalence of non-communicable diseases (NCDs) like cancer, diabetes, and cardiovascular conditions, which account for a significant portion of annual deaths. This, combined with a rapidly aging population where nearly 20% are over 60, creates a sustained demand for routine monitoring and early disease detection. Government health initiatives promoting preventive care further amplify the need for accessible and accurate diagnostic solutions across the country.

Government Initiatives and Healthcare Infrastructure Modernization

The Thai government's commitment to improving healthcare access and quality is a significant growth driver. Policies under the "Thailand 4.0" framework and investments in the Eastern Economic Corridor (EEC) are aimed at enhancing domestic medical device manufacturing and modernizing healthcare infrastructure. The Universal Coverage Scheme (UCS) ensures broad access to essential diagnostics, while the push for digitalization and adoption of advanced technologies like AI and molecular diagnostics in public and private hospitals supports market expansion.

Complex Regulatory Landscape and Inconsistent Reimbursement Policies

The adoption of advanced IVD technologies in Thailand is hindered by a complex regulatory environment and fragmented reimbursement policies. While basic diagnostic tests are covered under the national health system, reimbursement for newer, high-cost assays like molecular and genetic tests remains limited and subject to bureaucratic hurdles. These financial and regulatory challenges can slow the adoption of innovative diagnostic platforms, particularly in smaller healthcare facilities and rural areas.

Expansion Of Point-of-care And At-home Testing In A Decentralizing Healthcare Model

There is a significant opportunity in the expansion of point-of-care (POC) and direct-to-consumer (DTC) diagnostics. Driven by a tech-savvy population and the growth of telemedicine, there is rising demand for convenient, at-home testing for chronic disease management, infectious diseases, and general wellness. This shift toward decentralized healthcare creates new market avenues for manufacturers to provide user-friendly, approved self-testing kits, which can improve healthcare access in remote areas and support a more patient-centric approach to health management.

Competitive Landscape

The promising players operating in the Thailand in-vitro diagnostics industry include Roche Diagnostics (Thailand) Ltd., Abbott Laboratories, Siemens Healthineers, Thermo Fisher Scientific (Thailand) Co., Ltd., Beckman Coulter Diagnostics, Sysmex (Thailand) Co., Ltd., Becton, Dickinson and Company (BD), BioMérieux Thailand Ltd., Ortho Clinical Diagnostics (Thailand) Ltd., QIAGEN Thailand, Mindray Medical (Thailand) Limited, Bio-Rad Laboratories, Fujirebio Inc., HORIBA Limited, SEKISUI Diagnostics Southeast Asia, and others.

Thailand In-Vitro Diagnostics Market Key Segments

By Product & Service

Reagents & Consumables
- Clinical Chemistry Reagents
- Immunoassay Reagents (ELISA/CLIA)
- Molecular Master Mixes
- Hematology Controls
Instruments & Devices
- Chemistry Analyzers
- Immunoassay Systems
- Molecular Thermocyclers/Sequencers
- Hematology Analyzers
- POC Devices
Software & Services
- LIS, Data Analytics
- CRO/Testing Services

By Technique

Clinical Chemistry
- Metabolites
- Electrolytes
- Enzymes
Immunoassays
- ELISA / CLIA / CMIA
- Lateral-flow Rapid Tests
- Immunofluorescence
Molecular Diagnostics
- PCR
- Isothermal NAAT
- NGS
- In-situ Hybridization
Hematology & Coagulation
- CBC Analyzers
- Coagulation Panels
Microbiology
- Culture & Sensitivity
- MALDI-TOF
- Molecular ID
Urinalysis & Body Fluids
Other Techniques

By Testing Site / Channel

Central & Reference Laboratories
Hospital & Physician Labs
Point-of-Care & Retail
Home & Self-Testing

By Application / Disease Area

Infectious Diseases
Oncology
Cardiovascular Health
Endocrinology & Diabetes
Nephrology
Genetic & Prenatal Testing
Autoimmune Disorders
Drug Monitoring & Toxicology
Blood Screening & Typing
Other Indications

KEY PLAYERS

Roche Diagnostics (Thailand) Ltd.
Abbott Laboratories
Siemens Healthineers
Thermo Fisher Scientific (Thailand) Co., Ltd.
Beckman Coulter Diagnostics
Sysmex (Thailand) Co., Ltd.
Becton, Dickinson and Company (BD)
BioMérieux Thailand Ltd.
Ortho Clinical Diagnostics (Thailand) Ltd.
QIAGEN Thailand
Mindray Medical (Thailand) Limited
Bio-Rad Laboratories
Fujirebio Inc.
HORIBA Limited
SEKISUI Diagnostics Southeast Asia

REPORT SCOPE AND SEGMENTATION:

Parameters	Details
Market Size Value in 2023	USD 1.03 billion
Revenue Forecast in 2030	USD 1.63 billion
Value Growth Rate	CAGR of 6.3% from 2024 to 2030
Analysis Period	2023–2030
Base Year Considered	2023
Forecast Period	2024–2030
Market Size Estimation	Billion (USD)
Growth Factors	Growing Burden of Chronic Diseases and an Aging Population Fueling Diagnostic Demand Government Initiatives and Healthcare Infrastructure Modernization
Companies Profiled	15
Customization Scope	Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.
Pricing and Purchase Options	Avail customized purchase options to meet your exact research needs.

About the Author

Sikha Haritwal is a researcher with more than 5 years of experience. She has been keeping a close eye on several industry verticals, including construction & manufacturing, personal care products, and consumer electronics. She has avid interest in writing news articles and hopes to use blog as a platform to share her knowledge with others.

About the Reviewer

Supradip Baul is an accomplished business consultant and strategist with over a decade of rich experience in market intelligence, strategy, technology and business transformation. His work has included rigorous qualitative and quantitative analysis across multiple industries, helping clients shape investment decisions and long-term roadmaps. Earlier in his career, he was associated with Gartner, where he contributed to industry-leading reports and market share analyses. He has worked with leading global companies and holds an MBA with a dual specialization in Marketing and Finance.

1. 1.1. REPORT DESCRIPTION
2. 1.2. WHO SHOULD READ THIS REPORT
3. 1.3. KEY MARKET SEGMENTS
4. 1.4. RESEARCH METHODOLOGY
5. 1. 1.4.1 MARKET SIZE ESTIMATION METHODOLOGY
  2. 1. 1.4.1.1. TOP-DOWN AND BOTTOM-UP APPROACH
    2. 1.4.1.2. DEMAND AND SUPPLY-SIDE ANALYSIS
    3. 1.4.1.3. MACRO-INDICATOR APPROACH
  3. 1.4.2 DATA COLLECTION APPROACH
  4. 1. 1.4.2.1. PRIMARY DATA COLLECTION
    2. 1.4.2.2. SECONDARY DATA COLLECTION
  5. 1.4.3 SECONDARY DATA SOURCES
  6. 1.4.4 FORECASTING

1. 2.1. DEFINITION
2. 2.2. SCOPE

1. 3.1. MARKET SNAPSHOT, 2024 - 2030, MILLION USD

1. 4.1. MARKET DYNAMICS
2. 1. 4.1.1 DRIVERS
  2. 1. 4.1.1.1. GROWING BURDEN OF CHRONIC DISEASES AND AN AGING POPULATION FUELING DIAGNOSTIC DEMAND
    2. 4.1.1.2. GOVERNMENT INITIATIVES AND HEALTHCARE INFRASTRUCTURE MODERNIZATION
  3. 4.1.2 RESTRAINTS
  4. 1. 4.1.2.1. COMPLEX REGULATORY LANDSCAPE AND INCONSISTENT REIMBURSEMENT POLICIES
  5. 4.1.3 OPPORTUNITIES
  6. 1. 4.1.3.1. EXPANSION OF POINT-OF-CARE AND AT-HOME TESTING IN A DECENTRALIZING HEALTHCARE MODEL

1. 5.1. MARKET SHARE ANALYSIS OF TOP 10 THAILAND IN-VITRO DIAGNOSTICS PROVIDERS, 2024

1. 6.1 OVERVIEW
2. 6.2 REAGENTS AND CONSUMABLES MARKET
3. 1. 6.2.1 CLINICAL CHEMISTRY REAGENTS
  2. 6.2.2 IMMUNOASSAY REAGENTS (ELISA/CLIA)
  3. 6.2.3 MOLECULAR MASTER MIXES
  4. 6.2.4 HEMATOLOGY CONTROLS
4. 6.3 INSTRUMENTS AND DEVICES MARKET
5. 1. 6.3.1 CHEMISTRY ANALYZERS
  2. 6.3.2 IMMUNOASSAY SYSTEMS
  3. 6.3.3 MOLECULAR THERMOCYCLERS/SEQUENCERS
  4. 6.3.4 HEMATOLOGY ANALYZERS
  5. 6.3.5 POC DEVICES
6. 6.4 SOFTWARE AND SERVICES MARKET
7. 1. 6.4.1 LIS, DATA ANALYTICS
  2. 6.4.2 CRO/TESTING SERVICES

1. 7.1 OVERVIEW
2. 7.2 CLINICAL CHEMISTRY MARKET
3. 1. 7.2.1 METABOLITES
  2. 7.2.2 ELECTROLYTES
  3. 7.2.3 ENZYMES
4. 7.3 IMMUNOASSAYS MARKET
5. 1. 7.3.1 ELISA / CLIA / CMIA
  2. 7.3.2 LATERAL-FLOW RAPID TESTS
  3. 7.3.3 IMMUNOFLUORESCENCE
6. 7.4 MOLECULAR DIAGNOSTICS MARKET
7. 1. 7.4.1 PCR
  2. 7.4.2 ISOTHERMAL NAAT
  3. 7.4.3 NGS
  4. 7.4.4 IN-SITU HYBRIDIZATION
8. 7.5 HEMATOLOGY AND COAGULATION MARKET
9. 1. 7.5.1 CBC ANALYZERS
  2. 7.5.2 COAGULATION PANELS
10. 7.6 MICROBIOLOGY MARKET
11. 1. 7.6.1 CULTURE AND SENSITIVITY
  2. 7.6.2 MALDI-TOF
  3. 7.6.3 MOLECULAR ID
12. 7.7 URINALYSIS AND BODY FLUIDS MARKET
13. 7.8 OTHER TECHNIQUES MARKET

1. 8.1 OVERVIEW
2. 8.2 CENTRAL AND REFERENCE LABORATORIES MARKET
3. 8.3 HOSPITAL AND PHYSICIAN LABS MARKET
4. 8.4 POINT-OF-CARE AND RETAIL MARKET
5. 8.5 HOME AND SELF-TESTING MARKET

1. 9.1 OVERVIEW
2. 9.2 INFECTIOUS DISEASES MARKET
3. 9.3 ONCOLOGY MARKET
4. 9.4 CARDIOVASCULAR HEALTH MARKET
5. 9.5 ENDOCRINOLOGY AND DIABETES MARKET
6. 9.6 NEPHROLOGY MARKET
7. 9.7 GENETIC AND PRENATAL TESTING MARKET
8. 9.8 AUTOIMMUNE DISORDERS MARKET
9. 9.9 DRUG MONITORING AND TOXICOLOGY MARKET
10. 9.10 BLOOD SCREENING AND TYPING MARKET
11. 9.11 OTHER INDICATIONS MARKET

1. 10.1 ROCHE DIAGNOSTICS (THAILAND) LTD.
2. 1. 10.1.1 COMPANY OVERVIEW
  2. 10.1.2 COMPANY SNAPSHOT
  3. 10.1.3 OPERATING BUSINESS SEGMENTS
  4. 10.1.4 PRODUCT PORTFOLIO
  5. 10.1.5 BUSINESS PERFORMANCE
  6. 10.1.6 BUSINESS SEGMENTS
  7. 10.1.7 GEOGRAPHIC SEGMENTS
  8. 10.1.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.1.9 PRIMARY MARKET COMPETITORS
3. 10.2 ABBOTT LABORATORIES
4. 1. 10.2.1 COMPANY OVERVIEW
  2. 10.2.2 COMPANY SNAPSHOT
  3. 10.2.3 OPERATING BUSINESS SEGMENTS
  4. 10.2.4 PRODUCT PORTFOLIO
  5. 10.2.5 BUSINESS PERFORMANCE
  6. 10.2.6 BUSINESS SEGMENTS
  7. 10.2.7 GEOGRAPHIC SEGMENTS
  8. 10.2.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.2.9 PRIMARY MARKET COMPETITORS
5. 10.3 SIEMENS HEALTHINEERS
6. 1. 10.3.1 COMPANY OVERVIEW
  2. 10.3.2 COMPANY SNAPSHOT
  3. 10.3.3 OPERATING BUSINESS SEGMENTS
  4. 10.3.4 PRODUCT PORTFOLIO
  5. 10.3.5 BUSINESS PERFORMANCE
  6. 10.3.6 BUSINESS SEGMENTS
  7. 10.3.7 GEOGRAPHIC SEGMENTS
  8. 10.3.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.3.9 PRIMARY MARKET COMPETITORS
7. 10.4 THERMO FISHER SCIENTIFIC (THAILAND) CO., LTD.
8. 1. 10.4.1 COMPANY OVERVIEW
  2. 10.4.2 COMPANY SNAPSHOT
  3. 10.4.3 OPERATING BUSINESS SEGMENTS
  4. 10.4.4 PRODUCT PORTFOLIO
  5. 10.4.5 BUSINESS PERFORMANCE
  6. 10.4.6 BUSINESS SEGMENTS
  7. 10.4.7 GEOGRAPHIC SEGMENTS
  8. 10.4.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.4.9 PRIMARY MARKET COMPETITORS
9. 10.5 BECKMAN COULTER DIAGNOSTICS
10. 1. 10.5.1 COMPANY OVERVIEW
  2. 10.5.2 COMPANY SNAPSHOT
  3. 10.5.3 OPERATING BUSINESS SEGMENTS
  4. 10.5.4 PRODUCT PORTFOLIO
  5. 10.5.5 BUSINESS PERFORMANCE
  6. 10.5.6 BUSINESS SEGMENTS
  7. 10.5.7 GEOGRAPHIC SEGMENTS
  8. 10.5.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.5.9 PRIMARY MARKET COMPETITORS
11. 10.6 SYSMEX (THAILAND) CO., LTD.
12. 1. 10.6.1 COMPANY OVERVIEW
  2. 10.6.2 COMPANY SNAPSHOT
  3. 10.6.3 OPERATING BUSINESS SEGMENTS
  4. 10.6.4 PRODUCT PORTFOLIO
  5. 10.6.5 BUSINESS PERFORMANCE
  6. 10.6.6 BUSINESS SEGMENTS
  7. 10.6.7 GEOGRAPHIC SEGMENTS
  8. 10.6.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.6.9 PRIMARY MARKET COMPETITORS
13. 10.7 BECTON, DICKINSON AND COMPANY (BD)
14. 1. 10.7.1 COMPANY OVERVIEW
  2. 10.7.2 COMPANY SNAPSHOT
  3. 10.7.3 OPERATING BUSINESS SEGMENTS
  4. 10.7.4 PRODUCT PORTFOLIO
  5. 10.7.5 BUSINESS PERFORMANCE
  6. 10.7.6 BUSINESS SEGMENTS
  7. 10.7.7 GEOGRAPHIC SEGMENTS
  8. 10.7.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.7.9 PRIMARY MARKET COMPETITORS
15. 10.8 BIOMÉRIEUX THAILAND LTD.
16. 1. 10.8.1 COMPANY OVERVIEW
  2. 10.8.2 COMPANY SNAPSHOT
  3. 10.8.3 OPERATING BUSINESS SEGMENTS
  4. 10.8.4 PRODUCT PORTFOLIO
  5. 10.8.5 BUSINESS PERFORMANCE
  6. 10.8.6 BUSINESS SEGMENTS
  7. 10.8.7 GEOGRAPHIC SEGMENTS
  8. 10.8.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.8.9 PRIMARY MARKET COMPETITORS
17. 10.9 ORTHO CLINICAL DIAGNOSTICS (THAILAND) LTD.
18. 1. 10.9.1 COMPANY OVERVIEW
  2. 10.9.2 COMPANY SNAPSHOT
  3. 10.9.3 OPERATING BUSINESS SEGMENTS
  4. 10.9.4 PRODUCT PORTFOLIO
  5. 10.9.5 BUSINESS PERFORMANCE
  6. 10.9.6 BUSINESS SEGMENTS
  7. 10.9.7 GEOGRAPHIC SEGMENTS
  8. 10.9.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.9.9 PRIMARY MARKET COMPETITORS
19. 10.10 QIAGEN THAILAND
20. 1. 10.10.1 COMPANY OVERVIEW
  2. 10.10.2 COMPANY SNAPSHOT
  3. 10.10.3 OPERATING BUSINESS SEGMENTS
  4. 10.10.4 PRODUCT PORTFOLIO
  5. 10.10.5 BUSINESS PERFORMANCE
  6. 10.10.6 BUSINESS SEGMENTS
  7. 10.10.7 GEOGRAPHIC SEGMENTS
  8. 10.10.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.10.9 PRIMARY MARKET COMPETITORS
21. 10.11 MINDRAY MEDICAL (THAILAND) LIMITED
22. 1. 10.11.1 COMPANY OVERVIEW
  2. 10.11.2 COMPANY SNAPSHOT
  3. 10.11.3 OPERATING BUSINESS SEGMENTS
  4. 10.11.4 PRODUCT PORTFOLIO
  5. 10.11.5 BUSINESS PERFORMANCE
  6. 10.11.6 BUSINESS SEGMENTS
  7. 10.11.7 GEOGRAPHIC SEGMENTS
  8. 10.11.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.11.9 PRIMARY MARKET COMPETITORS
23. 10.12 BIO-RAD LABORATORIES
24. 1. 10.12.1 COMPANY OVERVIEW
  2. 10.12.2 COMPANY SNAPSHOT
  3. 10.12.3 OPERATING BUSINESS SEGMENTS
  4. 10.12.4 PRODUCT PORTFOLIO
  5. 10.12.5 BUSINESS PERFORMANCE
  6. 10.12.6 BUSINESS SEGMENTS
  7. 10.12.7 GEOGRAPHIC SEGMENTS
  8. 10.12.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.12.9 PRIMARY MARKET COMPETITORS
25. 10.13 FUJIREBIO INC.
26. 1. 10.13.1 COMPANY OVERVIEW
  2. 10.13.2 COMPANY SNAPSHOT
  3. 10.13.3 OPERATING BUSINESS SEGMENTS
  4. 10.13.4 PRODUCT PORTFOLIO
  5. 10.13.5 BUSINESS PERFORMANCE
  6. 10.13.6 BUSINESS SEGMENTS
  7. 10.13.7 GEOGRAPHIC SEGMENTS
  8. 10.13.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.13.9 PRIMARY MARKET COMPETITORS
27. 10.14 HORIBA LIMITED
28. 1. 10.14.1 COMPANY OVERVIEW
  2. 10.14.2 COMPANY SNAPSHOT
  3. 10.14.3 OPERATING BUSINESS SEGMENTS
  4. 10.14.4 PRODUCT PORTFOLIO
  5. 10.14.5 BUSINESS PERFORMANCE
  6. 10.14.6 BUSINESS SEGMENTS
  7. 10.14.7 GEOGRAPHIC SEGMENTS
  8. 10.14.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.14.9 PRIMARY MARKET COMPETITORS
29. 10.15 SEKISUI DIAGNOSTICS SOUTHEAST ASIA
30. 1. 10.15.1 COMPANY OVERVIEW
  2. 10.15.2 COMPANY SNAPSHOT
  3. 10.15.3 OPERATING BUSINESS SEGMENTS
  4. 10.15.4 PRODUCT PORTFOLIO
  5. 10.15.5 BUSINESS PERFORMANCE
  6. 10.15.6 BUSINESS SEGMENTS
  7. 10.15.7 GEOGRAPHIC SEGMENTS
  8. 10.15.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.15.9 PRIMARY MARKET COMPETITORS

TABLE 1. THAILAND IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT AND SERVICE, 2024-2030, (BILLION USD)
TABLE 2. REAGENTS AND CONSUMABLES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 3. CLINICAL CHEMISTRY REAGENTS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 4. IMMUNOASSAY REAGENTS (ELISA/CLIA), MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 5. MOLECULAR MASTER MIXES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 6. HEMATOLOGY CONTROLS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 7. INSTRUMENTS AND DEVICES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 8. CHEMISTRY ANALYZERS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 9. IMMUNOASSAY SYSTEMS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 10. MOLECULAR THERMOCYCLERS/SEQUENCERS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 11. HEMATOLOGY ANALYZERS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 12. POC DEVICES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 13. SOFTWARE AND SERVICES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 14. LIS, DATA ANALYTICS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 15. CRO/TESTING SERVICES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 16. THAILAND IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2024-2030, (BILLION USD)
TABLE 17. CLINICAL CHEMISTRY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 18. METABOLITES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 19. ELECTROLYTES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 20. ENZYMES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 21. IMMUNOASSAYS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 22. ELISA / CLIA / CMIA, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 23. LATERAL-FLOW RAPID TESTS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 24. IMMUNOFLUORESCENCE, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 25. MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 26. PCR, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 27. ISOTHERMAL NAAT, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 28. NGS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 29. IN-SITU HYBRIDIZATION, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 30. HEMATOLOGY AND COAGULATION, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 31. CBC ANALYZERS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 32. COAGULATION PANELS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 33. MICROBIOLOGY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 34. CULTURE AND SENSITIVITY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 35. MALDI-TOF, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 36. MOLECULAR ID, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 37. URINALYSIS AND BODY FLUIDS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 38. OTHER TECHNIQUES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 39. THAILAND IN-VITRO DIAGNOSTICS MARKET VALUE, BY TESTING SITE / CHANNEL, 2024-2030, (BILLION USD)
TABLE 40. CENTRAL AND REFERENCE LABORATORIES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 41. HOSPITAL AND PHYSICIAN LABS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 42. POINT-OF-CARE AND RETAIL, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 43. HOME AND SELF-TESTING, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 44. THAILAND IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION / DISEASE AREA, 2024-2030, (BILLION USD)
TABLE 45. INFECTIOUS DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 46. ONCOLOGY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 47. CARDIOVASCULAR HEALTH, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 48. ENDOCRINOLOGY AND DIABETES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 49. NEPHROLOGY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 50. GENETIC AND PRENATAL TESTING, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 51. AUTOIMMUNE DISORDERS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 52. DRUG MONITORING AND TOXICOLOGY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 53. BLOOD SCREENING AND TYPING, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 54. OTHER INDICATIONS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 55. ROCHE DIAGNOSTICS (THAILAND) LTD.: COMPANY SNAPSHOT
TABLE 56. ROCHE DIAGNOSTICS (THAILAND) LTD.: OPERATING BUSINESS SEGMENTS
TABLE 57. ROCHE DIAGNOSTICS (THAILAND) LTD.: PRODUCT PORTFOLIO
TABLE 58. ROCHE DIAGNOSTICS (THAILAND) LTD.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 59. ROCHE DIAGNOSTICS (THAILAND) LTD.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 60. ROCHE DIAGNOSTICS (THAILAND) LTD.: KEY STRATERGY
TABLE 61. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 62. ABBOTT LABORATORIES: OPERATING BUSINESS SEGMENTS
TABLE 63. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 64. ABBOTT LABORATORIES: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 65. ABBOTT LABORATORIES: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 66. ABBOTT LABORATORIES: KEY STRATERGY
TABLE 67. SIEMENS HEALTHINEERS: COMPANY SNAPSHOT
TABLE 68. SIEMENS HEALTHINEERS: OPERATING BUSINESS SEGMENTS
TABLE 69. SIEMENS HEALTHINEERS: PRODUCT PORTFOLIO
TABLE 70. SIEMENS HEALTHINEERS: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 71. SIEMENS HEALTHINEERS: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 72. SIEMENS HEALTHINEERS: KEY STRATERGY
TABLE 73. THERMO FISHER SCIENTIFIC (THAILAND) CO., LTD.: COMPANY SNAPSHOT
TABLE 74. THERMO FISHER SCIENTIFIC (THAILAND) CO., LTD.: OPERATING BUSINESS SEGMENTS
TABLE 75. THERMO FISHER SCIENTIFIC (THAILAND) CO., LTD.: PRODUCT PORTFOLIO
TABLE 76. THERMO FISHER SCIENTIFIC (THAILAND) CO., LTD.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 77. THERMO FISHER SCIENTIFIC (THAILAND) CO., LTD.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 78. THERMO FISHER SCIENTIFIC (THAILAND) CO., LTD.: KEY STRATERGY
TABLE 79. BECKMAN COULTER DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 80. BECKMAN COULTER DIAGNOSTICS: OPERATING BUSINESS SEGMENTS
TABLE 81. BECKMAN COULTER DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 82. BECKMAN COULTER DIAGNOSTICS: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 83. BECKMAN COULTER DIAGNOSTICS: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 84. BECKMAN COULTER DIAGNOSTICS: KEY STRATERGY
TABLE 85. SYSMEX (THAILAND) CO., LTD.: COMPANY SNAPSHOT
TABLE 86. SYSMEX (THAILAND) CO., LTD.: OPERATING BUSINESS SEGMENTS
TABLE 87. SYSMEX (THAILAND) CO., LTD.: PRODUCT PORTFOLIO
TABLE 88. SYSMEX (THAILAND) CO., LTD.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 89. SYSMEX (THAILAND) CO., LTD.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 90. SYSMEX (THAILAND) CO., LTD.: KEY STRATERGY
TABLE 91. BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT
TABLE 92. BECTON, DICKINSON AND COMPANY (BD): OPERATING BUSINESS SEGMENTS
TABLE 93. BECTON, DICKINSON AND COMPANY (BD): PRODUCT PORTFOLIO
TABLE 94. BECTON, DICKINSON AND COMPANY (BD): SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 95. BECTON, DICKINSON AND COMPANY (BD): SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 96. BECTON, DICKINSON AND COMPANY (BD): KEY STRATERGY
TABLE 97. BIOMÉRIEUX THAILAND LTD.: COMPANY SNAPSHOT
TABLE 98. BIOMÉRIEUX THAILAND LTD.: OPERATING BUSINESS SEGMENTS
TABLE 99. BIOMÉRIEUX THAILAND LTD.: PRODUCT PORTFOLIO
TABLE 100. BIOMÉRIEUX THAILAND LTD.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 101. BIOMÉRIEUX THAILAND LTD.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 102. BIOMÉRIEUX THAILAND LTD.: KEY STRATERGY
TABLE 103. ORTHO CLINICAL DIAGNOSTICS (THAILAND) LTD.: COMPANY SNAPSHOT
TABLE 104. ORTHO CLINICAL DIAGNOSTICS (THAILAND) LTD.: OPERATING BUSINESS SEGMENTS
TABLE 105. ORTHO CLINICAL DIAGNOSTICS (THAILAND) LTD.: PRODUCT PORTFOLIO
TABLE 106. ORTHO CLINICAL DIAGNOSTICS (THAILAND) LTD.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 107. ORTHO CLINICAL DIAGNOSTICS (THAILAND) LTD.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 108. ORTHO CLINICAL DIAGNOSTICS (THAILAND) LTD.: KEY STRATERGY
TABLE 109. QIAGEN THAILAND: COMPANY SNAPSHOT
TABLE 110. QIAGEN THAILAND: OPERATING BUSINESS SEGMENTS
TABLE 111. QIAGEN THAILAND: PRODUCT PORTFOLIO
TABLE 112. QIAGEN THAILAND: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 113. QIAGEN THAILAND: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 114. QIAGEN THAILAND: KEY STRATERGY
TABLE 115. MINDRAY MEDICAL (THAILAND) LIMITED: COMPANY SNAPSHOT
TABLE 116. MINDRAY MEDICAL (THAILAND) LIMITED: OPERATING BUSINESS SEGMENTS
TABLE 117. MINDRAY MEDICAL (THAILAND) LIMITED: PRODUCT PORTFOLIO
TABLE 118. MINDRAY MEDICAL (THAILAND) LIMITED: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 119. MINDRAY MEDICAL (THAILAND) LIMITED: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 120. MINDRAY MEDICAL (THAILAND) LIMITED: KEY STRATERGY
TABLE 121. BIO-RAD LABORATORIES: COMPANY SNAPSHOT
TABLE 122. BIO-RAD LABORATORIES: OPERATING BUSINESS SEGMENTS
TABLE 123. BIO-RAD LABORATORIES: PRODUCT PORTFOLIO
TABLE 124. BIO-RAD LABORATORIES: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 125. BIO-RAD LABORATORIES: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 126. BIO-RAD LABORATORIES: KEY STRATERGY
TABLE 127. FUJIREBIO INC.: COMPANY SNAPSHOT
TABLE 128. FUJIREBIO INC.: OPERATING BUSINESS SEGMENTS
TABLE 129. FUJIREBIO INC.: PRODUCT PORTFOLIO
TABLE 130. FUJIREBIO INC.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 131. FUJIREBIO INC.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 132. FUJIREBIO INC.: KEY STRATERGY
TABLE 133. HORIBA LIMITED: COMPANY SNAPSHOT
TABLE 134. HORIBA LIMITED: OPERATING BUSINESS SEGMENTS
TABLE 135. HORIBA LIMITED: PRODUCT PORTFOLIO
TABLE 136. HORIBA LIMITED: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 137. HORIBA LIMITED: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 138. HORIBA LIMITED: KEY STRATERGY
TABLE 139. SEKISUI DIAGNOSTICS SOUTHEAST ASIA: COMPANY SNAPSHOT
TABLE 140. SEKISUI DIAGNOSTICS SOUTHEAST ASIA: OPERATING BUSINESS SEGMENTS
TABLE 141. SEKISUI DIAGNOSTICS SOUTHEAST ASIA: PRODUCT PORTFOLIO
TABLE 142. SEKISUI DIAGNOSTICS SOUTHEAST ASIA: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 143. SEKISUI DIAGNOSTICS SOUTHEAST ASIA: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 144. SEKISUI DIAGNOSTICS SOUTHEAST ASIA: KEY STRATERGY

FIGURE 1. BARGAINING POWER OF SUPPLIERS
FIGURE 2. BARGAINING POWER OF BUYERS
FIGURE 3. DEGREE OF COMPETITION
FIGURE 4. THREAT OF SUBSTITUTE
FIGURE 5. THREAT OF NEW ENTRANTS
FIGURE 6. THAILAND IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT AND SERVICE, 2024-2030, (BILLION USD)
FIGURE 7. REAGENTS AND CONSUMABLES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 8. CLINICAL CHEMISTRY REAGENTS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 9. IMMUNOASSAY REAGENTS (ELISA/CLIA), MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 10. MOLECULAR MASTER MIXES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 11. HEMATOLOGY CONTROLS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 12. INSTRUMENTS AND DEVICES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 13. CHEMISTRY ANALYZERS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 14. IMMUNOASSAY SYSTEMS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 15. MOLECULAR THERMOCYCLERS/SEQUENCERS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 16. HEMATOLOGY ANALYZERS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 17. POC DEVICES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 18. SOFTWARE AND SERVICES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 19. LIS, DATA ANALYTICS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 20. CRO/TESTING SERVICES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 21. THAILAND IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2024-2030, (BILLION USD)
FIGURE 22. CLINICAL CHEMISTRY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 23. METABOLITES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 24. ELECTROLYTES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 25. ENZYMES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 26. IMMUNOASSAYS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 27. ELISA / CLIA / CMIA, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 28. LATERAL-FLOW RAPID TESTS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 29. IMMUNOFLUORESCENCE, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 30. MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 31. PCR, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 32. ISOTHERMAL NAAT, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 33. NGS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 34. IN-SITU HYBRIDIZATION, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 35. HEMATOLOGY AND COAGULATION, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 36. CBC ANALYZERS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 37. COAGULATION PANELS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 38. MICROBIOLOGY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 39. CULTURE AND SENSITIVITY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 40. MALDI-TOF, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 41. MOLECULAR ID, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 42. URINALYSIS AND BODY FLUIDS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 43. OTHER TECHNIQUES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 44. THAILAND IN-VITRO DIAGNOSTICS MARKET VALUE, BY TESTING SITE / CHANNEL, 2024-2030, (BILLION USD)
FIGURE 45. CENTRAL AND REFERENCE LABORATORIES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 46. HOSPITAL AND PHYSICIAN LABS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 47. POINT-OF-CARE AND RETAIL, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 48. HOME AND SELF-TESTING, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 49. THAILAND IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION / DISEASE AREA, 2024-2030, (BILLION USD)
FIGURE 50. INFECTIOUS DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 51. ONCOLOGY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 52. CARDIOVASCULAR HEALTH, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 53. ENDOCRINOLOGY AND DIABETES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 54. NEPHROLOGY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 55. GENETIC AND PRENATAL TESTING, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 56. AUTOIMMUNE DISORDERS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 57. DRUG MONITORING AND TOXICOLOGY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 58. BLOOD SCREENING AND TYPING, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 59. OTHER INDICATIONS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 60. ROCHE DIAGNOSTICS (THAILAND) LTD.: NET SALES, (2022-2024)
FIGURE 61. ROCHE DIAGNOSTICS (THAILAND) LTD.: PRIMARY MARKET COMPETITORS
FIGURE 62. ABBOTT LABORATORIES: NET SALES, (2022-2024)
FIGURE 63. ABBOTT LABORATORIES: PRIMARY MARKET COMPETITORS
FIGURE 64. SIEMENS HEALTHINEERS: NET SALES, (2022-2024)
FIGURE 65. SIEMENS HEALTHINEERS: PRIMARY MARKET COMPETITORS
FIGURE 66. THERMO FISHER SCIENTIFIC (THAILAND) CO., LTD.: NET SALES, (2022-2024)
FIGURE 67. THERMO FISHER SCIENTIFIC (THAILAND) CO., LTD.: PRIMARY MARKET COMPETITORS
FIGURE 68. BECKMAN COULTER DIAGNOSTICS: NET SALES, (2022-2024)
FIGURE 69. BECKMAN COULTER DIAGNOSTICS: PRIMARY MARKET COMPETITORS
FIGURE 70. SYSMEX (THAILAND) CO., LTD.: NET SALES, (2022-2024)
FIGURE 71. SYSMEX (THAILAND) CO., LTD.: PRIMARY MARKET COMPETITORS
FIGURE 72. BECTON, DICKINSON AND COMPANY (BD): NET SALES, (2022-2024)
FIGURE 73. BECTON, DICKINSON AND COMPANY (BD): PRIMARY MARKET COMPETITORS
FIGURE 74. BIOMÉRIEUX THAILAND LTD.: NET SALES, (2022-2024)
FIGURE 75. BIOMÉRIEUX THAILAND LTD.: PRIMARY MARKET COMPETITORS
FIGURE 76. ORTHO CLINICAL DIAGNOSTICS (THAILAND) LTD.: NET SALES, (2022-2024)
FIGURE 77. ORTHO CLINICAL DIAGNOSTICS (THAILAND) LTD.: PRIMARY MARKET COMPETITORS
FIGURE 78. QIAGEN THAILAND: NET SALES, (2022-2024)
FIGURE 79. QIAGEN THAILAND: PRIMARY MARKET COMPETITORS
FIGURE 80. MINDRAY MEDICAL (THAILAND) LIMITED: NET SALES, (2022-2024)
FIGURE 81. MINDRAY MEDICAL (THAILAND) LIMITED: PRIMARY MARKET COMPETITORS
FIGURE 82. BIO-RAD LABORATORIES: NET SALES, (2022-2024)
FIGURE 83. BIO-RAD LABORATORIES: PRIMARY MARKET COMPETITORS
FIGURE 84. FUJIREBIO INC.: NET SALES, (2022-2024)
FIGURE 85. FUJIREBIO INC.: PRIMARY MARKET COMPETITORS
FIGURE 86. HORIBA LIMITED: NET SALES, (2022-2024)
FIGURE 87. HORIBA LIMITED: PRIMARY MARKET COMPETITORS
FIGURE 88. SEKISUI DIAGNOSTICS SOUTHEAST ASIA: NET SALES, (2022-2024)
FIGURE 89. SEKISUI DIAGNOSTICS SOUTHEAST ASIA: PRIMARY MARKET COMPETITORS

At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.

Research Landscape

We navigate the world of research with two primary approaches:

Qualitative Approach

Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.

Quantitative Research

In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.

Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.

Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.

Our Specialized Toolbox for Industry-Specific Market Research

We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:

Information Procurement

The stage entails acquiring market data or relevant information through various sources and methodologies.

Market Research Approach

We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.

Porters Five Forces Analysis

We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.

SWOT Analysis

We conduct SWOT analysis to understand market trends, identify potential threats, capitalize on opportunities, and assess our strengths and weaknesses.

Forecasting

We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.

Frequently Asked Questions

The Thailand in-vitro diagnostics market is estimated to reach USD 1.63 billion by 2030.

The key players in the Thailand in-vitro diagnostics market include Roche Diagnostics (Thailand) Ltd., Abbott Laboratories, Siemens Healthineers, Thermo Fisher Scientific (Thailand) Co., Ltd., Beckman Coulter Diagnostics, Sysmex (Thailand) Co., Ltd., Becton, Dickinson and Company (BD), BioMérieux Thailand Ltd., Ortho Clinical Diagnostics (Thailand) Ltd., QIAGEN Thailand, Mindray Medical (Thailand) Limited, Bio-Rad Laboratories, Fujirebio Inc., HORIBA Limited, SEKISUI Diagnostics Southeast Asia, and others.

The Thailand in-vitro diagnostics market was estimate to reach USD 1.03 billion in 2023.

High costs associated with research, development, and regulatory approval are significant factors restraining the market growth.

Introduction of Point-of-Care Testing Solutions creates opportunities for the in-vitro diagnostics in the coming future.

Download Free Sample

Full Name *

Please Enter Full Name

Business Email Id *

Please Enter Valid Email ID

Phone Number *

Please enter Country Code and Phone No

Message

Please enter message

Yes, I have read the Privacy Policy

Multi User

$2,575

Single User

$1,575

Enterprise

$3,875

Datapack

$1,975

Download Sample

Inquire Before Buying

Speak to Our Analyst

Share with Peers

Request Sample